Semaglutide shows potential as dual therapy for metabolic dysfunction and alcohol-related liver disease

Metabolic dysfunction-associated alcohol-related liver disease (MAALD) represents a growing clinical challenge, characterized by the synergistic progression of liver damage due to both metabolic risk factors and alcohol consumption. Unlike traditional alcoholic liver disease (ALD) or metabolic dysfunction-associated steatotic liver disease (MASLD), MAALD involves a complex interplay of inflammation, steatosis, and fibrosis driven by both etiologies. Current therapeutic approaches are often fragmented, focusing either on strict alcohol abstinence or managing metabolic comorbidities like obesity and type 2 diabetes. This leaves a critical gap for integrated treatments that can simultaneously target the underlying metabolic dysregulation and mitigate the harmful effects of alcohol on the liver. GLP-1 receptor agonists (GLP-1RAs), such as semaglutide, have demonstrated significant benefits in improving metabolic health, reducing hepatic steatosis, and exerting anti-inflammatory effects, making them compelling candidates for exploring their broader utility in complex conditions like MAALD. The need for a unified therapeutic strategy is paramount to improve patient outcomes and reduce disease progression.